ENTYVIO® Outcomes in Real-world, Bio-naïve Ulcerative Colitis and Crohn’s Disease Patients (EVOLVE)—Greece (EVOLVE-Greece)

Study identification

• EU PAS number:
  EUPAS19669
• Study ID:
  36412
• Official title and acronym:
  ENTYVIO® Outcomes in Real-world, Bio-naïve Ulcerative Colitis and Crohn’s Disease Patients (EVOLVE)—Greece (EVOLVE-Greece)
• DARWIN EU® study:
  No
• Study countries:
  Greece
• Study description:
  The study aims to evaluate long-term (>6 months) real-world treatment patterns, clinical effectiveness and safety of vedolizumab (VDZ) in biologic-naïve ulcerative colitis (UC) and Crohn’s disease (CD) patients in Greece.
• Study status:
  Finalised

Research institutions and networks

Institutions

Evaggelismos Hospital

General Hospital of Nikaia Nikaia, Venizeleio Hospital Crete, University Hospital Crete, Erythros Stavros Athens, Patra Rio University Hospital Agrinio, Euroclinic Athens, Laiko Hospital Athens, Alexandra Hospital Athina, Iatriko Athinon Marousi Athens, Erythros Stavros Athens

Study timelines

Date when funding contract was signed

Actual: 30/05/2017

Study start date

Planned: 21/05/2018

Actual: 24/05/2018

Data analysis start date

Planned: 31/01/2019

Actual: 28/02/2019

Date of final study report

Planned: 28/02/2019

Actual: 29/04/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Takeda Development Centre Europe Ltd

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

VDZ-5036